Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
102.55
(
-1.80%
)
Bitcoin
70,365.99
(
0.67%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 72978

Tuesday, 02/10/2009 6:33:16 AM

Tuesday, February 10, 2009 6:33:16 AM

Post# of 257262
Momenta’s Mantra on FoB’s (with BIO-CEO webcast link):

“It’s much harder to reverse-engineer a biologic than to make a new biologic… we see many players stating that they’re going to enter the follow-on biologics business, but we see very few with clearly defined or clearly differentiated strategies. Our view is that you need to have a differentiated strategy… that’s what we’re going after: …technology differentiation through characterization”

—Craig Wheeler, MNTA CEO, 9-Feb-2009 (at BIO-CEO conference)

Link to webcast replay:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=*MNTA&item_id=2079572


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today